Immunotherapy eradicates metastases with reversible defects in MHC class I expression (Q39546174)

12 September 2017

Immunotherapy eradicates metastases with reversible defects in MHC class I expression (English)

1 reference

12 September 2017

1 reference

8

Federico Garrido

1 reference

12 September 2017

Cristina Garrido

1

1 reference

12 September 2017

Irene Romero

2

1 reference

12 September 2017

Enrique Berruguilla

3

1 reference

12 September 2017

Bárbara Cancela

4

1 reference

12 September 2017

Ignacio Algarra

5

1 reference

12 September 2017

Antonia Collado

6

1 reference

12 September 2017

Angel García-Lora

7

1 reference

12 September 2017

8 May 2011

1 reference

Cancer Immunology, Immunotherapy

12 September 2017

1 reference

12 September 2017

60

1 reference

12 September 2017

9

1 reference

12 September 2017

1257-1268

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-011-1027-1

12 September 2017

0 references

cites work

Progress in human tumour immunology and immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Immunotherapy of distant metastatic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Polyclonal CTL Responses Observed in Melanoma Patients Vaccinated with Dendritic Cells Pulsed with a MAGE-3.A1 Peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Human T cell responses against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Cancer and immune response: old and new evidence for future challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

HLA class I antigen abnormalities and immune escape by malignant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

A weakly tumorigenic phenotype with high MHC class-I expression is associated with high metastatic potential after surgical removal of the primary murine fibrosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Finding the tumor copycat. Therapy fails, patients don't

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Identification of the protein components of protein-bound polysaccharide (PSK) that interact with NKL cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Protein-bound polysaccharide K augments IL-2 production from murine mesenteric lymph node CD4+ T cells by modulating T cell receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

NK sensitivity and lung clearance of MHC-class-I-deficient cells within a heterogeneous fibrosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Innate immune recognition of viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1027-1

10.1007/S00262-011-1027-1

21 January 2018

Identifiers

DOI

1 reference

release_djwzmc6qpzb5ncngfw3acvpgue

12 September 2017

0 references

1 reference